Continuous positive airway pressure may improve hypertension in patients with obstructive sleep apnea-hypopnea syndrome by inhibiting inflammation and oxidative stress

Introduction The work was designed to investigate the effect of continuous positive airway pressure (CPAP) on hypertension in obstructive sleep apnea-hypopnea syndrome (OSAHS) patients and to elucidate the underlying mechanisms. Methods We examined the effect of CPAP on blood pressure and biomarkers reflecting inflammation and oxidative stress, and investigated the correlation between changes in blood pressure and the biomarkers. Results CPAP significantly improved clinic, ambulatory and home blood pressure (p < 0.05). The hypotensive effect of CPAP was positively correlated with the decrease of interleukin-6, C-reactive protein, NADPH oxidase and malonaldehyde. Conclusions CPAP has a significant antihypertensive effect on OSAHS patients, especially nocturnal hypertension, possibly by counteracting inflammation and oxidative stress.

[1]  C. Eulenburg,et al.  Effect of Obstructive Sleep Apnea and CPAP Treatment on Cardiovascular Outcomes in Acute Coronary Syndrome in the RICCADSA Trial , 2020, Journal of clinical medicine.

[2]  P. Hanly,et al.  Nocturnal hypoxemia severity influences the effect of CPAP therapy on renal renin-angiotensin-aldosterone system activity in humans with obstructive sleep apnea. , 2020, Sleep.

[3]  D. Gaita,et al.  Long-Term Effects of Continuous Positive Airway Pressure (CPAP) Therapy on Obesity and Cardiovascular Comorbidities in Patients with Obstructive Sleep Apnea and Resistant Hypertension—An Observational Study , 2020, Journal of clinical medicine.

[4]  Gang Zhao,et al.  Continuous positive airway pressure effectively ameliorates arrhythmias in patients with obstructive sleep apnea-hypopnea via counteracting the inflammation. , 2020, American journal of otolaryngology.

[5]  A. Yıldırım,et al.  Assessment of the relationship between endocan and obstructive sleep apnea severity , 2020, Archives of medical science : AMS.

[6]  M. Al-Ajam,et al.  Treatment of obstructive sleep apnea with CPAP improves chronic inflammation measured by neutrophil-to-lymphocyte ratio. , 2020, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[7]  W. Aronow,et al.  Obstructive sleep apnoea and cardiovascular disease: a literature review , 2019, Archives of medical science : AMS.

[8]  A. Boss,et al.  Impact of hypertension on cerebral microvascular structure in CPAP-treated obstructive sleep apnoea patients: a diffusion magnetic resonance imaging study , 2019, Neuroradiology.

[9]  F. Beuschlein,et al.  Endocrine responses during CPAP withdrawal in obstructive sleep apnoea: data from two randomised controlled trials , 2019, Thorax.

[10]  Nabanita Kundu,et al.  Reassessing the effects of continuous positive airway pressure (CPAP) on arterial stiffness and peripheral blood derived CD34+ progenitor cells in subjects with sleep apnea , 2019, Stem Cell Research & Therapy.

[11]  J. Pépin,et al.  Reduction in sympathetic tone in patients with obstructive sleep apnoea: is fixed CPAP more effective than APAP? A randomised, parallel trial protocol , 2019, BMJ Open.

[12]  J. Stradling,et al.  Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA , 2014, Thorax.

[13]  J. Stradling,et al.  OSA and hypertension: do we know all the answers? , 2013, Chest.

[14]  David Watts Apnea , 1997, The Lancet.